Cefaclor [3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; Lilly 99638] and cefatrizine {7-D-a-amino-a-[4-hydroxylphenyl]-acetamido -[3-(1H-1,2,3-triazol-5-thio)-methyl] -
3-cephem-4-carboxylic acid; BL-S640, SK&F 06771} are semisynthetic broad-spectrum cephalosporin antibiotics active against both gram-positive and gram-negative bacteria including penicillin-resistant organisms (1, 2, 6) . Metabolic studies in animals have shown that cefaclor is readily absorbed from the gastrointestinal tract as intact drug (8) . Cefatrizine also is absorbed from the gastrointestinal tract of rodents and is effective orally against experimental infections in mice (7) . In vitro, cefatrizine is said to be more active than cephalothin or cephalexin against clinically important gram-negative and gram-positive bacteria not including Haemophilus influenzae and Streptococcus pneumoniae (10) but is less active than cephradine, cephalothin, and cefazolin against Staphylococcus aureus (9) . Cefaclor recently has been reported to be more active in vitro than either cephalexin or cephradine against a large number of gram-positive and gram-negative pathogens but less resistant to staphylococcal penicillinase (2) .
The purpose of this study was to compare the in vitro activity of cefaclor with that of cefatrizine and, further, to compare these two new oral cephalosporins with cephalexin, cephradine, and cephaloglycin, three oral cephalosporins now used clinically.
MATERIALS AND METHODS
Antibiotics. Cefaclor (Lilly 99638, lot S1-100-6C, activity of 961 ,ug/mg), cephaloglycin (lot 9NK09, activity of 890 ,ug/mg), and cephalexin monohydrate (lot S1-89-6B, activity of 940 ,ug/mg) were obtained from Lilly Research Laboratories. Cefatrizine (BL-S64OPG, lot 75-F396, activity of 868 ,g/mg) was obtained from Bristol Laboratories, and cephradine monohydrate (batch NNO83NE, activity of 967 ,ugl mg) was obtained from the Squibb Institute for Medical Research. Solutions of cefatrizine, cephradine, and cephaloglycin were prepared in sterile distilled water. Cefaclor was dissolved in 0.1 M Sorenson buffer, pH 4.5, and cepahlexin was dissolved in 1.0% sorenson buffer, pH 6.0. All solutions were sterilized by membrane filtration.
Susceptibility testing. A modification of the standardized ICS agar dilution procedure was used (5). The test medium was Mueller-Hinton agar, which was supplemented with blood for use with fastidious organisms or with additional agar, for a total of 4%, for use with Proteus species. Test concentrations of drugs ranged from 128 to 0.063 ,ug/ml (actual adjusted activity). Plates containing cefatrizine, cephradine, or cephalexin were prepared 1 to 2 days in advance; plates containing cefaclor or cephaloglycin were prepared the same day as used. Inocula were prepared from overnight broth cultures grown in Mueller-Hinton broth. 
RESULTS
In vitro inhibitory activities of cefaclor, cefatrizine, cephalexin, cephaloglycin, and cephradine against gram-positive bacteria are presented, as cumulative percentages of inhibition, in Table 1 and against gram-negative organisms in Table 2 .
Generally, cefatrizine and cefaclor were the most active of the five oral cephalosporins agains susceptible gram-positive cocci. Eighty percent of S. aureus isolates was inhibited by cefatrizine in a concentration of 1.0 ,g/ml, whereas a similar concentration of cephradine inhibited only 56% of isolates tested. Cefaclor was significantly less active against S. aureus than either cefatrizine, cephalexin, or cephradine (P < 0.01, < 0.05, and < 0.02, respectively) but similar in activity to cephaloglycin.
Cefaclor and cefatrizine were the most active cephalosporins against S. pyogenes; all 20 iso-although 4 .0 Hg of cephalexin and cephradine lates were inhibited by 1.0 ug of either drug per ml inhibited 95 and 100%o of isolates, reper ml. Cephaloglycin was the next most ac-spectively. Differences between cefaclor or cefative; in a concentration of 1.0 ,ug/ml, it inhib-trizine and cephalexin and cephradine were ited 90% of isolates. Differences between cefaclor significant (P < 0.05). and cefatrizine and between cefatrizine and Cefaclor and cefatrizine were the most active cephaloglycin were not significant. Cephalexin cephalosporins against S. pneumoniae, both and cephradine were the least active against were over twofold more active than cephadrine S. pyogenes and, based upon a comparison of G and nearly fourfold more active than cephavalues, were approximately two to four times lexin. Differences between cefaclor or cefatriless active than either cefaclor or cefatrizine, zine and cephalexin were highly significant (P Mg of cefatrizine per ml inhibited 48% of isolates. Cefaclor and cephradine were the next most active, inhibiting 100 and 88% of isolates, respectively, when used in a concentration of 64 ,ug/ml. Differences between cefaclor and cefatrizine were not significant (P > 0.05), but differences between cefatrizine and cephradine were (P < 0.001). Differences between cefaclor or cefatrizine and cephalexin or cephaloglycin were highly significant (P < 0.001).
Generally, cefaclor and cefatrizine were the most active cephalosporins against gram-negative aerobic species (Table 2) . This was most pronounced in studies with K. pneumoniae. At a concentration of 1.0 gg/ml, cefatrizine and cefaclor inhibited 62 and 76%, respectively, of isolates tested. No inhibition was observed with cephalexin, cephaloglycin, or cephradine at this same concentration. Differences between cefaclor and cefatrizine and the other three compounds were significant (P < 0.05). Cefaclor and cefatrizine were the most active against E. coli, and cefaclor was 1.5 to 5.5 times more active than either cephalexin, cephaloglycin, or cephradine; differences between cefaclor and the latter drugs were significant (P < 0.001). Cefatrizine was two to five times more active than either cephaloglycin or cephradine (P < 0.001) but only slightly more active than cephalexin (P = 0.02).
Striking differences were observed in results with E. aerogenes and E. cloacae. Cefatrizine and cephaloglycin were the most active cephalosporins against E. aerogenes; in a concentration of 16 ,ug/ml, they inhibited 55 and 46%, respectively. In contrast, similar concentrations inhibited only 14% of isolates of E. cloacae. Both cefaclor and cefatrizine were twofold more active than either cephalexin or cephradine against E. aerogenes but only slightly more active than cephaloglycin. Only cephradine and cefatrizine demonstrated any degree of activity against E. cloacae, inhibiting 29% of isolates at 32 Mg of either drug and 71 and 50%, respectively, at 64 Mg of either drug per ml.
Two micrograms of cefaclor per ml was the most active cephalosporin against susceptible isolates of P. mirabilis with inhibition of 79% of isolates; however, five isolates were resistant. Both cefaclor and cefatrizine were fourfold or more active than either cephalexin or cephradine. Cephaloglycin was the third most active cephalosporin against P. mirabilis. Dif- ferences between cephaloglycin and cefaclor or cefatrizine were not significant, although cephaloglycin was twofold less active than cefaclor.
Cefatrizine was the most active drug against indole-positive Proteus species, being some fourfold more active than cefaclor and six times more active than the least active drugs, cephalexin and cephradine. The activity of cefaclor was significantly less than that of cefatrizine (P < 0.001) but did not differ significantly from those of cephalexin, cephaloglycin, and cephradine.
DISCUSSION
Both cefaclor and cefatrizine have been shown to be readily absorbed from the gastrointestinal tracts of experimental animals (1, 8) . In humans, it has been stated that peak cefaclor plasma concentrations are obtained 30 to 45 min after oral administration; these ranged as high as 30 ,ug/ml, depending upon dose. Cefatrizine also is absorbed orally and is said to produce higher peak serum levels and to have a longer biological half-life than either cefazolin or cephalexin (1) .
Our data show cefaclor to be comparable to cephradine and cephaloglycin in terms of in vitro activity against S. pyogenes and somewhat superior to cephalexin. Cefaclor also is comparable if not superior to cephalexin in terms of activity against S. pyogenes and S. aureus. Like cephalexin and cephaloglycin, cefaclor was devoid of clinically significant activity against enterococci.
In our study, cefaclor clearly was the most active drug against gram-negative bacteria including K. pneumoniae, E. coli, and P. mirabilis. Cefaclor also clearly was superior to cephalexin, cephaloglycin, and cephradine against these organisms as well as againstE. aerogenes but not E. cloacae. These results agree with those of Bill and Washington (2) .
Cefatrizine was comparable, if not identical, to cefaclor in terms of activity against S. pyogenes and S. pneumoniae and superior to cephalexin against S. aureus, S. pyogenes, S. pneumoniae, and enterococci. These latter re- The activity of cefatrizine against gram-negative bacteria was, in most instances, comparable to that of cefaclor. As previously reported by Actor et al. (1) and Del Busto et al. (4) , cefatrizine was, in our study, superior to cephalexin against E. coli, K. pneumoniae, and P. mirabilis. Our study also shows cefatrizine and cefaclor to be comparable against E. coli and E. aerogenes and superior to cephalexin, cephaloglycin, or cephradine. Cefatrizine was less active than cefaclor but again superior to cephalexin, cephaloglycin, or cephradine against K. pneumoniae. Cefatrizine also was highly active against indole-positive Proteus species.
In conclusion, our data indicate that the in vitro activities of cefaclor and cefatrizine are similar to each other and generally superior to those of cephalexin, cephaloglycin, or cephradine against clinical isolates of most gram-positive cocci, except enterococci, as well as against E. coli, K. pneumoniae, and E. aerogenes. Both cefaclor and cefatrizine have unique activities, cefaclor being uniquely active against P. mirabilis and cefatrizine against indole-positive Proteus species as well as against some enterococci.
